UnitedHealthcare Prefers Basaglar Biosimilar At Lantus' Expense
Executive Summary
UnitedHealthcare's decision to exclude Lantus in favor of Basaglar begs the question of how low biosimilar pricing will go, amid soaring diabetes costs.
You may also be interested in...
Lilly/BI's Basaglar: A Rosier Outlook For US Biosimilars?
Sales of the insulin glargine product in its first full year on the market were strong at $432.1m, but Lilly said it is offering steep rebates in exchange for market access and it's not clear that the growth is sustainable if more copies enter the market.
Lilly/BI's Basaglar: A Rosier Outlook For US Biosimilars?
Sales of the insulin glargine product in its first full year on the market were strong at $432.1m, but Lilly said it is offering steep rebates in exchange for market access and it's not clear that the growth is sustainable if more copies enter the market.
Merck's Lantus Copy Lusduna Poised For US Market Pending Litigation
The Merck and Samsung Bioepis formulation of Sanofi's insulin glargine was tentatively approved by FDA, a designation that permits the drug to enter the market pending the resolution of ongoing patent litigation.